Endophthalmitis following intravitreal anti-VEGF injections in ambulatory surgical centre facility: incidence, management and outcome.
Srimati Kanuri Santhamma Centre for Vitreo Retinal diseases, Kallam Anji Reddy campus, L V Prasad Eye Institute, , Hyderabad, Andhra Pradesh, India.
Kopal
K
Mithal
Annie
A
Mathai
Avinash
A
Pathengay
Subhadra
S
Jalali
Nidhi
N
Relhan
Swapna Reddy
SR
Motukupally
Savitri
S
Sharma
Taraprasad
T
Das
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D000068258:Bevacizumab; D009877:Endophthalmitis / Q000139:chemically induced* / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D006801:Humans; D015994:Incidence; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab